CodeBreaK 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C-mutant solid tumors. Eligible patients must have received a prior line of systemic ...

The results are the first from a completed pivotal Phase 2 study in NSCLC with a median follow-up of more than one year MISSISSAUGA, ON, Feb. 1, 2021 /CNW/ - Amgen has announced results from the Phase ...

Lumakras outperformed chemotherapy in reducing the risk of progression or death and improving quality of life for patients with KRAS G12C-mutated non-small cell lung cancer, study results showed.

CodeBreaK 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C-mutant solid tumors. 9 Eligible patients must have received a prior line of systemic ...

Hello. I'm David Kerr, professor of cancer medicine at the University of Oxford. One of the things I like to talk about are some of the breakthrough studies in colorectal cancer, but also to see if we ...

CodeBreaK 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C-mutant solid tumors. 7.8 Eligible patients must have received a prior line of systemic ...

THOUSAND OAKS, Calif., Oct. 7, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol ...

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study ...